<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Taba">
 <table frame="hsides" rules="groups">
  <tbody>
   <tr>
    <td align="left">Respiratory viral infections represent one of the most feared complications in the hematological patient in terms of both clinical severity and mortality.</td>
   </tr>
   <tr>
    <td align="left">Influenza (IFV) and parainfluenza viruses (PIV), respiratory syncytial virus (RSV), adenovirus (AdV), rhinovirus (RhV) and coronavirus (CoV) are the most relevant agents involved in respiratory infections.</td>
   </tr>
   <tr>
    <td align="left">Respiratory infections in immunocompromised patients have an initial involvement of the upper respiratory tract; the feared progression to the lower respiratory tract is strictly related to clinical conditions of patients as well as several risk factors.</td>
   </tr>
   <tr>
    <td align="left">Defining effective therapeutic and prophylactic strategies is challenging, especially considering the variability spectrum of onco-hematological patients and the variety of respiratory viruses involved.</td>
   </tr>
   <tr>
    <td align="left">Although the scientific community recognizes the relevance of these infections, there is no uniform consensus on available clinical management options, diagnostic and therapeutic tools, and preventive and prophylaxis measures.</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
